Ginkgo Bioworks(NYSE) DNA

Ginkgo Bioworks Holdings, Inc. helps companies design custom cells. These cells help companies make new medicines and better crops. The company sells research services and robotic tools to customers.

How Does Ginkgo Engineering Work?

• Cell Engineering Solutions: Multiyear research projects that deliver custom biological parts, such as enzyme sequences or engineered cell lines; includes service fees and royalty rights.
• Cell Engineering Tools: Robotic automation systems and data packages sold to customers who want to conduct their own biological research in-house.
• Autonomous Lab: Robotic hardware systems that generate large-scale data for biological modeling and design using generative artificial intelligence tools.
• Genetic Medicine R&D: Specialized research services including protein engineering and bioprocess development for healthcare and agricultural industries.

Adapting to a Changing Market

• Divested the Biosecurity business on April 3, 2026, to focus resources on core cell engineering and technology tools.
• Launched a major restructuring plan in the second quarter of 2024 to reduce costs and prioritize the development of laboratory automation systems.
• Established a stock sale program in Sept. 2025 to raise up to $100.0 million for corporate purposes and technology development.
• Expanded service offerings in 2024 to include technology tools that allow customers to use the company’s automation and data directly.

The Power of Data

Ginkgo uses automated robotic systems to run many biological experiments at the same time. These systems generate data sets that improve the success rate and speed of future cell designs.

Checking the Ledger

• Revenue was $39.6 million for the six months ended June 30, 2026, down from $77.4 million year over year.
• The net loss from continuing operations was $133.4 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $302.2 million as of June 30, 2026.
• Research and development expenses fell to $96.1 million for the six months ended June 30, 2026, down from $124.3 million year over year.
• Net proceeds from the stock sale agreement reached $34.6 million as of June 30, 2026.

The Long-Term Path

Ginkgo is shifting its focus toward providing standardized technology tools and reducing high operational costs. Its recent divestitures and restructuring efforts reflect a strategy to streamline its business model for future sustainability.